- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07484139
H&N NEO-COMBAT XL : XL-092 (Zanzalintinib) et Pembrolizumab (Keytruda) en néoadjuvant dans le carcinome épidermoïde de la cavité buccale résécable chirurgicalement, HPV négatif (OCSCC) (NEO COMBAT XL)
H&N NEO-COMBAT XL : Néo-adjuvant XL-092 (Zanzalintinib) et Pembrolizumab (Keytruda) dans le carcinome épidermoïde de la cavité buccale (CECB) résécable chirurgicalement, HPV négatif
This is a multicenter, single arm Phase 2B study in subjects with locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease. The study will assess the combination of neoadjuvant XL092 and pembrolizumab for safety and improvement of pathologic response rates compared to historical standard of care with perioperative pembrolizumab. The primary objective is to estimate the pathologic response rate defined as either pathological complete response (pCR), which is the absence of residual viable tumor, or major pathologic response (MPR), which is <10% of residual tumor following the completion of neoadjuvant therapy and surgery. The study will be conducted in two stages. Per Simon's Stage 1, 11 patients will be enrolled. Simon Stage 2 will be gated on multiple factors. If ≥2 pathologic response is observed (pCR or MPR), the trial will proceed with cohort expansion and enroll an additional 15 patients for a total of 26 patients.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Rose Hall
- Numéro de téléphone: 919-984-0000
- E-mail: rose_hall@med.unc.edu
Sauvegarde des contacts de l'étude
- Nom: Shamina Williams
- Numéro de téléphone: 919-984-0000
- E-mail: shamina_williams@med.unc.edu
Lieux d'étude
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Pas encore de recrutement
- Emory University
-
Contact:
- Nikki C Schmitt
- E-mail: Nicole.cherie.schmitt@emory.edu
-
Chercheur principal:
- Nikki C Schmitt, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- University of North Carolina at Chapel Hill
-
Contact:
- Siddharth Sheth, MD
- E-mail: siddharth.sheth@unchealth.unc.edu
-
Contact:
- Rose Hall, MSW
- Numéro de téléphone: 984-974-8440
- E-mail: rose_hall@med.unc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Pas encore de recrutement
- Thomas Jefferson University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
- Age ≥ 18 years at the time of consent.
- Tumors must have PD-L1 Combined Positive Score (CPS) ≥ 1.
- ECOG or Karnofsky Performance Status of 0-1
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) within 30 days prior to treatment .
Exclusion Criteria:
- Known HPV-positive cancer
- Active infection requiring systemic therapy.
- Prior treatment with XL-092
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Locally advanced oral cavity squamous cell carcinoma
Locally advanced oral cavity squamous cell carcinoma (OCSCC) with surgically resectable disease. |
60 mg oral once a day 200 mg intravenous for 30 minutes in every 21 days for |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rate of pathologic response
Délai: Up to 66 days
|
Rate of pathologic response, assessed following surgery, will be defined as either pathological complete response (pCR), which is the absence of residual viable tumor or major pathological response (MPR), which is <10% residual tumor. |
Up to 66 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Neoadjuvant Adverse Events
Délai: Up to 66 days
|
Safety will be defined as the rate of treatment emergent adverse events with neoadjuvant XL-092 and pembrolizumab (CTCAE v5.0). |
Up to 66 days
|
|
Events Free Survival (EFS)
Délai: Up to 15 months
|
EFS will be defined as the time from first treatment to an event which may include disease progression, discontinuation of the treatment for any reason, or death from any cause, where disease progression will be determined based on Radiographic response will be measured according to Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1). RECIST indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Up to 15 months
|
|
Objective response rate (ORR)
Délai: Up to 15 months
|
ORR following neoadjuvant therapy: an objective response will be classified per the Radiographic response will be measured according to Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1) if a partial or complete response is observed. RECIST indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Up to 15 months
|
|
Time to surgery
Délai: Up to 66 days
|
Time to surgery: defined as the time from completion of neoadjuvant therapy to date of surgery. Individuals who do not receive surgery due to progressive disease, non-TEAE death or individuals who experience surgery delays due to toxicity will not be counted. |
Up to 66 days
|
|
Overall survival (OS)
Délai: Up to 15 months
|
OS is defined as the time from time of first treatment to death due to any cause. |
Up to 15 months
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Siddharth Sheth, MD, UNC Lineberger Comprehensive Cancer Center
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LCCC2517
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .